



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### **Genetic evidence for a link between favorable adiposity and lower risk of type 2 diabetes, hypertension and heart disease**

**Citation for published version:**

Yaghootkar, H, Lotta, LA, Tyrrell, J, Smit, RAJ, Jones, SE, Donnelly, L, Beaumont, R, Campbell, A, Tuke, MA, Hayward, C, Ruth, KS, Padmanabhan, S, Jukema, JW, Palmer, CC, Hattersley, A, Freathy, RM, Langenberg, C, Wareham, NJ, Wood, AR, Murray, A, Weedon, MN, Sattar, N, Pearson, E, Scott, RA & Frayling, TM 2016, 'Genetic evidence for a link between favorable adiposity and lower risk of type 2 diabetes, hypertension and heart disease' *Diabetes*, vol 65, no. 8, pp. 2448-2460. DOI: 10.2337/db15-1671

**Digital Object Identifier (DOI):**

[10.2337/db15-1671](https://doi.org/10.2337/db15-1671)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Diabetes

**Publisher Rights Statement:**

This is an author-created, uncopyedited electronic version of an article accepted for publication in *Diabetes*. The American Diabetes Association (ADA), publisher of *Diabetes*, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of *Diabetes* in print and online at [Diabetes URL: http://diabetes.diabetesjournals.org](http://diabetes.diabetesjournals.org)

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



**Title:**

**Genetic evidence for a link between favorable adiposity and lower risk of type 2 diabetes, hypertension and heart disease.**

**Short running title:** Favorable adiposity and lower cardiometabolic risk

**Author list:**

Hanieh Yaghootkar<sup>1</sup>, Luca A. Lotta<sup>2</sup>, Jessica Tyrrell<sup>1</sup>, Roelof A. J. Smit<sup>3,4</sup>, Sam E. Jones<sup>1</sup>, Louise Donnelly<sup>5</sup>, Robin Beaumont<sup>1</sup>, Archie Campbell<sup>6</sup>, Marcus A. Tuke<sup>1</sup>, Caroline Hayward<sup>7</sup>, Katherine S. Ruth<sup>1</sup>, Sandosh Padmanabhan<sup>8</sup>, J. Wouter Jukema<sup>9,10</sup>, Colin C. Palmer<sup>5</sup>, Andrew Hattersley<sup>11</sup>, Rachel M. Freathy<sup>1</sup>, Claudia Langenberg<sup>2</sup>, Nicholas J. Wareham<sup>2</sup>, Andrew R. Wood<sup>1</sup>, Anna Murray<sup>1</sup>, Michael N. Weedon<sup>1</sup>, Naveed Sattar<sup>12</sup>, Ewan Pearson<sup>5</sup>, Robert A. Scott<sup>2</sup>, Timothy M. Frayling<sup>1</sup>

**Affiliations:**

1. Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, U.K.
2. MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge Biomedical Campus, University of Cambridge School of Clinical Medicine, Cambridge, U.K.
3. Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.
4. Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands.
5. Division of Cardiovascular & Diabetes Medicine, Medical Research Institute, University of Dundee, Dundee, Scotland, U.K.
6. Generation Scotland, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, U.K.
7. MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, U.K.
8. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
9. Department of Cardiology and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.
10. Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands.
11. Genetics of Diabetes, University of Exeter Medical School, Exeter, U.K.
12. Faculty of Medicine, BHF Glasgow Cardiovascular Research Centre, Glasgow, UK.

**Corresponding author:**

Timothy M Frayling

University of Exeter Medical School

RILD building Level 3

Royal Devon & Exeter Hospital

Barrack Road

Exeter

EX2 5DW

E-mail: [T.M.Frayling@exeter.ac.uk](mailto:T.M.Frayling@exeter.ac.uk)

**Work count:** 4,029

**Number of tables and figures:** 5

## Abstract

Recent genetic studies have identified some alleles associated with higher BMI but lower risk of type 2 diabetes, hypertension and heart disease. These “favorable adiposity” alleles are collectively associated with lower insulin levels and higher subcutaneous-to-visceral adipose tissue ratio and may protect from disease through higher adipose storage capacity. We aimed to use data from 164,609 individuals from the UK Biobank and five other studies to replicate associations between a genetic score of 11 favorable adiposity variants and adiposity and risk of disease, test for interactions between BMI and favorable adiposity genetics and test effects separately in men and women.

In the UK Biobank the 50% of individuals carrying the most favorable adiposity alleles had higher BMIs ( $0.120 \text{ Kg/m}^2$  [0.066,0.174];  $p=1\text{E-}5$ ) and higher body fat percentage (0.301 % [0.230,0.372];  $p=1\text{E-}16$ ) compared to the 50% of individuals carrying the fewest alleles. For a given BMI, the 50% of individuals carrying the most favourable adiposity alleles were at: 0.837 OR [0.784,0.894] lower risk of type 2 diabetes ( $p=1\text{E-}7$ ), -0.859 mmHg [-1.099,-0.618] lower systolic ( $p=3\text{E-}12$ ) and -0.394 mmHg [-0.534,-0.254] lower diastolic blood pressure ( $p=4\text{E-}8$ ), 0.935 OR [0.911,0.958] lower risk of hypertension ( $p=1\text{E-}7$ ) and 0.921 OR [0.872,0.973] lower risk of heart disease ( $p=3\text{E-}3$ ). In women, these associations could be explained by the observation that the alleles associated with higher BMI but lower risk of disease were also associated with a favourable body fat distribution, with a lower waist-hip ratio (-0.004 [-0.005,-0.003] 50% vs 50%;  $p=3\text{E-}14$ ) but in men, the favourable adiposity alleles were associated with higher waist circumference (0.454 cm [0.267,0.641] 50% vs 50%;  $p=2\text{E-}6$ ) and higher waist-hip ratio (0.0013 [0.0003,0.0024] 50% vs 50%;  $p=0.01$ ). Results were strengthened when meta-analysing with five additional studies. There was no

evidence of interaction between a genetic score consisting of known BMI variants and the favorable adiposity genetic score.

In conclusion, different molecular mechanisms that lead to higher body fat percentage (with greater subcutaneous storage capacity) can have different impacts on cardiometabolic disease risk. While higher BMI is associated with higher risk of diseases, better fat storage capacity could reduce the risk.

## Introduction

Some obese individuals are metabolically healthy whilst some normal weight individuals have an elevated risk of type 2 diabetes, heart disease and hypertension (1; 2). One of the many factors that mean two people of similar BMI can have very different risks of cardiometabolic disease is the capacity of subcutaneous adipose tissue to store excess lipids. The “adipose tissue expandability” hypothesis states that when adipose tissue stops expanding by cell size or number, with continued weight gain the lipid accumulates preferentially in ectopic sites such as cardiac, liver and beta cells which can lead to heart disease, hypertension, insulin resistance and type 2 diabetes (3). Single gene studies of extreme forms of obesity and lipodystrophy, two apparently opposite conditions, support the “adipose tissue expandability” hypothesis (4; 5).

Studies of the general population show that most common genetic variants associated with higher BMI are associated with higher risk of type 2 diabetes, hypertension and heart disease, either individually as in the case of the variant in the *FTO* gene (6), or as a genetic risk score (7). However, recent studies have also identified common genetic variants where alleles associated with lower insulin resistance (8) are also associated with higher BMI and body fat percentage and lower risk of type 2 diabetes, hypertension and heart disease (9-11). These variants include those in the *IRS1* gene, where the common allele associated with higher body fat percentage is associated with lower fasting insulin, triglyceride and LDL-cholesterol levels, lower insulin secretion and higher insulin sensitivity, adiponectin, HDL-cholesterol and leptin levels (9). A genetic score of ten (11) or eleven (10) alleles including that near *IRS1* had a similar profile with the alleles associated with higher BMI also being associated with lower circulating levels of triglyceride and fatty liver markers but higher adiponectin, HDL-cholesterol and SHBG levels and lower risk of type 2 diabetes, hypertension and heart

disease. These “favorable adiposity” alleles were also associated collectively with a higher subcutaneous-to-visceral adipose tissue ratio (10) and higher body fat mass (11), and may protect from disease by increasing the capacity of subcutaneous adipose tissue to store excess calories as lipids (10). These observations suggest that different molecular mechanisms that lead to higher BMI and higher body fat percentage can have different impacts on metabolic disease, some of which are paradoxical to epidemiological correlations.

In this study we had three aims. First, to replicate the association of a genetic score of 11 favorable adiposity variants (10) with higher BMI and body fat percentage, but lower risk of the three diseases of the “metabolic syndrome” - type 2 diabetes, hypertension and heart disease. Given the apparently paradoxical associations between higher BMI and lower risk of disease we wanted to replicate the effects in large studies not part of previous genome wide association study meta-analyses to both confirm associations and establish their true effects in population-based studies. Second, to test if a genetic score of favorable adiposity variants interacted with a genetic score of variants identified as associated primarily with BMI. Identifying interactions between genetic variants has proven very difficult, but the availability of individual level data in the UK Biobank provides an opportunity to identify individuals who may be at especially high or low genetic risk of disease if they carry certain combinations of alleles. These BMI variants consisted of those recently identified as associated with BMI in a meta-analysis of 250,000 individuals (12). Third, we aimed to test the role of the favorable adiposity alleles in disease predisposition in men and women separately given the differences in body fat distribution between the two sexes. We used the UK Biobank study to address these questions because it is a single large relatively homogeneous population based study. We used five additional studies not part of previous GWA studies to provide additional statistical confidence of our findings.

## Methods

### *Study samples*

All details of the UK Biobank and 5 additional studies are given in **table S1**.

**The UK Biobank:** The UK Biobank recruited over 500,000 individuals aged 37-73 years (99.5% were between 40 and 69 years) in 2006-2010 from across the UK. Participants provided a range of information via questionnaires and interviews (e.g. demographics, health status, lifestyle) and anthropometric measurements, blood pressure readings, blood, urine and saliva samples were taken for future analysis; this has been described in more detail elsewhere (13). We used 120,286 individuals of British descent from the initial UK Biobank dataset. We did not include other ethnic groups, because individually they were underpowered to detect previously reported effects. British-descent was defined as individuals who both self-identified as white British and were confirmed as ancestrally Caucasian using principal components analyses (PCA) of genome wide genetic information. This dataset underwent extensive central quality control including the exclusion of the majority of third degree or closer relatives from a genetic kinship analysis of 96% of individuals. We performed an additional round of principal components analysis (PCA) on these 120,286 UK Biobank participants. We selected 95,535 independent SNPs (pairwise  $r^2 < 0.1$ ) directly genotyped with a minor allele frequency (MAF)  $\geq 2.5\%$  and missingness  $< 1.5\%$  across all UK Biobank participants with genetic data available at the time of this study ( $N=152,732$ ), and with HWE  $P > 1 \times 10^{-6}$  within the white British participants. Principal components were subsequently generated using FlashPCA (14).

**Additional studies:** To provide further evidence for the role of favorable adiposity alleles we used a total of 50,753 individuals from 5 studies: EXTEND (6,504 individuals of white European descent collected from South West England), GoDARTS (4086 individuals of



white European descent collected from North Scotland) (15), Generation Scotland: Scottish Family Health Study (14,064 individuals of white European descent collected from Scotland) (16), PROSPER (5,244 individuals of white European descent collected from Scotland, Ireland and the Netherlands) (17; 18) and EPIC-Norfolk (20,855 individuals of white European descent collected from Norfolk) (19). We chose these studies because they were not part of the published GWAS used in previous studies (10).

### ***Phenotypes***

#### ***Measures of adiposity***

The UK Biobank: We used BMI and bio-impedance measures of body fat percentage measured by the Tanita BC418MA body composition analyser.

We used body fat percentage as it is a more accurate measure of body composition. The UK Biobank provided two measures of BMI – one calculated from  $\text{weight(kg)/height(m)}^2$  and one using height and electrical impedance to quantify mass. We excluded individuals ( $N=1,172$  out of 500,000) with differences  $>4.56$  SDs between impedance and normal BMI measures where both variables were available (94% of data). If only one measure of BMI was available this was used ( $N=7,290$ ).

Additional studies: We used BMI and body fat percentage as measures of adiposity. Body fat percentage was measured using Tanita digital scale in EXTEND, bio-impedance on a Tanita digital scale in Generation Scotland and Tanita digital scale in EPIC-Norfolk.

#### ***Measures of disease and disease related traits.***

The UK Biobank: We used 3 cardiometabolic disease outcomes: type 2 diabetes, hypertension (also represented by continuous measures of systolic and diastolic blood

pressure) and heart disease – all using baseline data and following similar definitions to those used in previous genome wide association studies.

We defined type 2 diabetes using baseline data and following similar definitions to those used in previous genome wide association studies. We defined type 2 diabetes cases if 3 criteria were present: i) reports of either type 2 diabetes or generic diabetes at the interview, ii) at least one year gap from diagnosis without requiring insulin iii) reported age at diagnosis over the age of 35 years to limit the numbers of individuals with slow-progressing autoimmune diabetes or monogenic forms. Individuals not reporting an age of diagnosis were excluded. We also excluded individuals diagnosed with diabetes within the year prior to the baseline study visit as we were unable to determine whether they were using insulin within the first year. Controls were individuals not fulfilling these criteria.

We defined hypertensive cases as individuals with systolic blood pressure of  $>140$  mmHg, or a diastolic blood pressure of  $>90$  mmHg, or the report of blood pressure medication usage. Controls were individuals not fulfilling these criteria. For the analysis of systolic and diastolic blood pressure, we corrected blood pressure measures in people on antihypertensive drugs by adding 15 mmHg to systolic and 10 mmHg to diastolic blood pressure, in keeping with the approach taken by genome wide association studies. As a sensitivity analysis, we used blood pressure measures in individuals who were not on blood pressure medications.

We defined heart disease cases if individuals reported angina and/or a heart attack at the interview stage. We defined Controls as individuals without these conditions. As a sensitivity analysis, we used heart disease cases as only those with heart attack at the interview stage.

Additional studies: We used 3 metabolic disease outcomes: type 2 diabetes, hypertension (also represented by continuous measures of systolic and diastolic blood pressure) and heart disease.

EXTEND defined type 2 diabetes as self-reported or having HbA1c >6.4% and excluded in case subjects, 1) individuals aged at diagnosis <35 or >70 years; 2) individuals who needed insulin treatment within 1 year of diagnosis; and 3) individuals aged <45 years whose age at diagnosis was not known at the time of study; and in control subjects, 1) individuals aged <35 or >70 years at the time of study; and 2) individuals with HbA1c >6.4%. Hypertension and heart disease were self-reported.

GoDARTS defined Diabetes as status at recruitment (case/control). Hypertensive cases were defined as individuals with systolic blood pressure of >140 mmHg, or a diastolic blood pressure of > 90 mmHg at recruitment. Blood pressure was corrected by adding 15 mmHg to systolic and 10 mmHg to diastolic blood pressure in hypertensive cases if they were on blood pressure medications.

Generation Scotland defined Diabetes cases by identifying linkage to prescribing data where drugs prescribed were in BNF code group 6.1. The prescriptions were also used to show which participants were taking blood pressure lowering drugs (BNF code 2.4, 2.5, 2.6). Blood pressure was measured twice during a clinic visit and the mean systolic and diastolic values used. Diabetes, hypertension and heart disease were self-reported on a questionnaire at the time of participation.

PROSPER defined type 2 diabetes by (i) known type 2 diabetes, and/or (ii) fasting glucose  $\geq 7$  mmol/L, and/or (iii) use of antidiabetic drugs (any oral hypoglycaemic agent or insulin). Hypertensive cases were defined as those on use of antihypertensive medication. They defined heart disease as combination of prevalent (baseline history of myocardial infarction, CABG/PTCA, angina) and incident (coronary heart disease death (definite plus suspect), non-fatal myocardial infarction (definite plus suspect), CABG/PTCA) events. All endpoints

were validated by a blinded events committee. For detailed end point definitions, please see appendix B in (18).

EPIC-Norfolk used both prevalent and incident type 2 diabetes to define type 2 diabetes cases. They used treatment-adjusted variables for systolic and diastolic blood pressure, and blood pressure medication to define hypertension. They defined heart disease as self-reported myocardial infarction at baseline and incident myocardial infarction.

### ***Selection of Genetic variants associated with favorable adiposity***

We chose 11 variants previously identified by a hierarchical clustering approach as sharing features of monogenic lipodystrophic insulin resistance, including a surrogate measure of insulin resistance, subcutaneous to visceral adipose tissue ratio from CT scans, lipids, markers of fatty liver disease, and adiponectin (**table S2**) (10). We refer to the BMI raising alleles as “favorable adiposity” alleles throughout the manuscript.

### ***Selection of Genetic variants associated with BMI***

We selected 69 variants as associated with BMI and refer to the BMI raising alleles as “BMI” alleles throughout the manuscript. These 69 were selected from 76 common genetic variants associated with BMI at genome wide significance in the Genetic Investigation of ANthropometric Traits (GIANT) consortium studies of up to 339,224 individuals (**table S3**) (12). We limited the BMI SNPs to those that were associated with BMI in the analysis of all European ancestry individuals and did not include those that only reached genome-wide levels of statistical confidence in one-sex only, or one-strata only. Variants were also excluded if classified as a secondary signal within a locus. Three SNPs were excluded due to potential pleiotropy (rs11030104 (*BDNF* reward phenotypes), rs13107325 (*SLC39A8* lipids, blood pressure), rs3888190 (*SH2B1* multiple traits)), 3 SNPs were not in Hardy-Weinberg

Equilibrium (HWE) (rs17001654, rs2075650, rs9925964) and one SNP was unavailable (rs2033529) (**table S3**).

### ***Genotypes***

The UK Biobank: We extracted genotypes from UK Biobank's imputation dataset and used genotype dosage values prior to association testing. Individual genotypes were excluded if HWE  $P < E^{-6}$  or if imputation quality  $< 0.9$ . We confirmed that the 11 favorable adiposity variants and the 69 BMI variants were imputed with high quality by comparing to the directly genotyped data, available in 120,286 UK Biobank individuals of genetically confirmed British ancestry. Details of imputation quality are given in **tables S2** and **S3**.

Additional studies: **Table S4** describes the imputation/genotyping methods used by each study.

### ***Genetic score analysis***

We constructed 2 genetic scores: (i) the genetic score of 11 favorable adiposity variants was the number of favorable adiposity alleles carried by each individual weighted based on their effect on fasting insulin, (ii) the genetic score of 69 BMI variants was the number of alleles associated with higher BMI carried by each individual. As a sensitivity analysis, we conducted a genetic score of favorable adiposity based on variants that were individually associated with body fat percentage in the UK Biobank study.

### ***Statistical analysis***

For the analysis of individual variants we assumed an additive model. We used 5 covariates including age, sex, genotyping platform (two were used), study centre and five within UK genetic principle components. As smoking has a big effect on BMI, we ran a sensitivity

analysis using smoking as a covariate in the UK Biobank data in addition to the above covariates.

We used the genetic risk score for BMI in order to test the hypothesis that a general genetic predisposition to higher BMI interacted with a general predisposition to favorable adiposity. We did not investigate specific variants for interaction. For this interaction analysis between two genetic scores (69 BMI variants and 11 favorable adiposity variants) and measures of blood pressure and cardiometabolic disease risk, we included the respective interaction terms in the models (e.g. interaction term = BMI genetic score x favorable adiposity genetic score).

### ***Meta-analysis***

We meta-analysed results across the 6 studies using fixed-effects inverse variance-weighted meta-analysis. We tested for any evidence of heterogeneity between the results using the Cochran Q test.

### ***Sex dichotomized analysis***

To assess whether or not associations differed between sexes, we repeated the inverse-variance meta-analyses in men and women separately in the UK Biobank study. Sex-difference P values were calculated by the Cochran Q test.

### ***Assessing disease risk in individuals with a genetic susceptibility to high BMI.***

To provide additional context for the interaction analysis, we dichotomized the 11 favorable adiposity genetic score and the BMI genetic score into two groups based on the median of the two genetic score distributions. We considered individuals with above median favorable adiposity genetic score and below median BMI genetic score as having the lowest cardiometabolic disease risk and used them as a reference group. By comparing to the

reference group, we tested blood pressure and the risk of type 2 diabetes, hypertension and heart disease in 3 groups of individuals based on the two genetic score distributions: i) those at below median of the favorable adiposity genetic score and below median of the BMI genetic score, ii) those at above median of the favorable adiposity genetic score and above median of the BMI genetic score, and iii) those at below median of the favorable adiposity genetic score and above median of the BMI genetic score.

## Results

*A genetic score of 11 favorable adiposity variants was associated with higher BMI and body fat percentage in the UK Biobank.*

The genetic score of 11 favorable adiposity variants was associated with higher body fat percentage and higher BMI in the UK Biobank with very high levels of statistical confidence. Each additional favourable adiposity weighted allele was associated with a 0.126% ([0.104,0.149];  $p=8E-28$ ) higher fat percentage and 0.046 Kg/m<sup>2</sup> ([0.029,0.063];  $p=2E-7$ ) higher BMI. These effects meant that the 50% of people carrying the most favourable adiposity alleles had on average 0.301 % ([0.230,0.372];  $p=1E-16$ ) additional adipose tissue and were 0.120 Kg/m<sup>2</sup> ([0.066,0.174];  $p=1E-5$ ) heavier than the 50% of people carrying the fewest favourable adiposity alleles (**figure 1a**). The 11 variants in a multivariable analysis explained 0.04% variance in BMI levels and 0.2% variance in body fat percentage in the UK Biobank study (N=119,688) after correcting for age, sex, genotyping array, study centre and within UK principle components. The analysis of the favorable adiposity genetic score against absolute measures of body fat mass and body fat-free mass showed that the effect of the 11 favorable adiposity variants was driven by fat-mass not fat-free mass and the genetic score was not associated with height (**figure 1a; table 1**). The genetic score effects were predominantly driven by 7 of the 11 variants that were individually associated with body fat percentage at  $p<3E-5$  – those in or near the *LYPLAL1*, *PPARG*, *PEPD*, *GRB14*, *IRS1*, *ANKRD55* and *FAM13A* genes (**table S5**)

*A genetic score of 11 favorable adiposity variants was associated with lower waist circumference and waist-hip ratio in women, but higher waist circumference and waist hip ratio in men.*



In the UK Biobank, the genetic score of 11 favorable adiposity variants associated with higher BMI was associated with a favourable body fat distribution, as measured by a lower waist-hip ratio (-0.0006 [-0.0009, -0.0004] per allele;  $p=2E-7$ ) but these effects were dichotomised by sex. In women, the alleles associated with higher BMI were also associated with a lower waist-hip ratio (-0.0017 [-0.0021, -0.0014] per allele;  $p=9E-23$ ), an effect driven by a larger hip circumference (0.16 [0.11, 0.21] per allele;  $p=1E-9$ ), with little effect on waist circumference (-0.04 [-0.10, 0.02] per allele;  $p=0.2$ ). In men, the favourable adiposity genetic risk score associated with higher BMI was associated with higher waist circumference (0.17 [0.11, 0.23] per allele;  $p=1E-8$ ), higher hip circumference (0.12 [0.08, 0.16] per allele;  $p=1E-8$ ) and slightly higher waist-hip ratio (0.0005 [0.0002, 0.0009] per allele;  $p=0.001$ ) (**table S6**). These effects meant that the 50% of men carrying the most favourable adiposity alleles had a waist circumference 0.45 cm larger ([0.267,0.641];  $p=2E-6$ ) than the 50% of men carrying the fewest favourable adiposity alleles. These associations were consistent when meta-analysing the UK Biobank data with 3 additional studies (**figure 2**). These effects were even stronger when limiting the favorable adiposity genetic score to the 7 variants that were individually associated with body fat percentage at  $p<3E-5$  – those in or near the *LYPLAL1*, *PPARG*, *PEPD*, *GRB14*, *IRSI*, *ANKRD55* and *FAM13A* genes (**table S6**).

***A genetic score of 11 favorable adiposity variants was associated with lower risk of type 2 diabetes.***

Despite being associated with higher fat mass, each additional favourable adiposity weighted allele was associated with a 0.943 OR ([0.924,0.963];  $p=2E-8$ ) lower risk of type 2 diabetes in the UK Biobank. This association was statistically stronger when meta-analysing the UK Biobank data with five additional studies (**table S7**). These effects meant that the 50% of people carrying the most favourable adiposity alleles had a 0.895 OR ([0.840,0.954];  $p=6E-4$ )

lower risk of type 2 diabetes than the 50% of people carrying the fewest favourable adiposity alleles (**figure 1b**; **table S8**). Despite the dichotomised body fat distribution, these effects were consistent in men and women (**table S9**) and across 6 different bands of BMI (<25,25-30,30-35,35-40 and >40; **figure 3**). The effect was similar when we used smoking as a covariate (**table S10**) and, as expected, was stronger when we used 7 variants that were individually associated with body fat percentage at  $p < 3 \times 10^{-5}$  (**table S11**).

We next used the genetic score for favorable adiposity and a genetic risk score for BMI in order to test the hypothesis that a general genetic predisposition to higher BMI interacted with a general predisposition to favorable adiposity. We did not investigate specific variants for interaction. There was no evidence of interaction between the genetic score of favorable adiposity alleles and the genetic score of 69 BMI alleles ( $P_{\text{interaction}} > 0.05$ ). Despite being more overweight, carrying more favorable adiposity alleles than average reduced the risk of type 2 diabetes in the 50% of individuals most genetically predisposed to high BMI (OR: 0.885 [0.813,0.965];  $p = 0.005$ ; **figure 4**; **table S12**). These effects were consistent with those expected given additive effects of the alleles.

***A genetic score of 11 favorable adiposity variants was associated with lower risk of hypertension.***

Despite being associated with higher fat mass, each additional favourable adiposity weighted allele was associated with a 0.255 mmHg ([0.334,0.176];  $p = 2 \times 10^{-10}$ ) lower systolic blood pressure, 0.096 mmHg ([0.143,0.048];  $p = 7 \times 10^{-5}$ ) lower diastolic blood pressure and 0.982 OR ([0.974,0.989];  $p = 3 \times 10^{-6}$ ) lower risk of hypertension in the UK Biobank (**table 1**). These associations were statistically stronger when meta-analysing the UK Biobank data with five additional studies (**table S7**). These effects meant that the 50% of people carrying the most favourable adiposity alleles had a 0.732 mmHg ([0.980,0.484];  $p = 7 \times 10^{-9}$ ) lower systolic blood

pressure, 0.292 mmHg ([0.440,0.144];  $p=1E-4$ ) lower diastolic blood pressure and 0.946 OR ([0.923,0.969];  $p=7E-6$ ) lower risk of hypertension than the 50% of people carrying the fewest favourable adiposity alleles (**figure 1b; table S8**). Despite the dichotomised body fat distribution, these effects were consistent in men and women (**table S9**) and across 6 different bands of BMI (<25,25-30,30-35,35-40 and >40; **figure 3**). These effects were similar when we used smoking as a covariate or when we excluded individuals on blood pressure medication (**table S10**). As expected, the effects were stronger when we used 7 variants that were individually associated with body fat percentage at  $p<3E-5$  (**table S11**).

There was no evidence of interaction between the genetic score of favorable adiposity alleles and the genetic score of 69 BMI alleles on systolic or diastolic blood pressure or the risk of hypertension ( $P_{\text{interaction}} = 0.1, 0.07$  and  $0.7$  respectively). Despite being more overweight, carrying more favorable adiposity alleles than average reduced the risk of hypertension in the 50% of individuals most genetically predisposed to high BMI (OR: 0.960 [0.927,0.994];  $p=0.02$ ) and lowered their average systolic blood pressure (-0.475 [-0.829,-0.121];  $p=0.009$ ) but had no detectable effect on diastolic blood pressure (**figure 4; table S12**). These effects were consistent with those expected given additive effects of the alleles.

***A Genetic score of 11 favorable adiposity variants was associated with lower risk of heart disease.***

Despite being associated with higher fat mass, each additional favourable adiposity weighted allele was associated with a 0.967 OR ([0.950,0.984];  $p=1E-4$ ) lower risk of heart disease in the UK Biobank (**table 1**). This association was consistent when meta-analysing the UK Biobank data with five additional studies (**table S7**). Based on the UK Biobank study, these effects meant that the 50% of people carrying the most favourable adiposity alleles had a 0.942 OR ([0.892,0.994];  $p=0.03$ ) lower risk of heart disease (**figure 1b; table S8**). Despite

the dichotomised body fat distribution, these effects were consistent in men and women, although they did not reach  $p < 0.05$  in women, where there were fewer heart disease cases (**table S8**) These effects were similar when we used smoking as a covariate or when we considered only individuals with the history of heart attack as cases (**table S10**). The effects were stronger when we used 7 variants that were individually associated with body fat percentage at  $p < 3E-5$  (**table S11**).

There was no evidence of interaction between the genetic score of favorable adiposity alleles and the genetic score of 69 BMI alleles ( $P_{\text{interaction}} = 0.5$ ). Carrying more favorable adiposity alleles than average in the genetically predisposed individuals to high BMI had no detectable effect on risk of heart disease (**figure 4; table S12**).

#### ***Effects of favourable adiposity alleles on disease increase when correcting for BMI***

As expected given that the favourable adiposity genetic score is associated with higher BMI, when we corrected for BMI, associations with reduced disease risk strengthened (**table S13**). These results showed that, for a given BMI, the 50% of individuals carrying the most favourable adiposity alleles were at lower risk of type 2 diabetes (OR: 0.837 [0.784,0.894];  $p = 1E-7$ ), hypertension (OR: 0.935 [0.911,0.958];  $p = 1E-7$ ) and heart disease (OR: 0.921 [0.872,0.973];  $p = 0.003$ ) and had lower blood pressure (systolic: -0.859 mmHg [-1.099,-0.618];  $p = 3E-12$  and diastolic: -0.394 mmHg [-0.534,-0.254];  $p = 4E-8$ ). These effects were consistent in men and women.

## Discussion

We replicated with very high statistical confidence results from previous studies showing that in combination, 11 common genetic variants are associated with higher adiposity but lower risk of type 2 diabetes, hypertension and heart disease. In total we used 164,609 individuals from 6 studies including the UK Biobank and included 6,735, 82,512 and 8,881 individuals with type 2 diabetes, hypertension and heart disease, respectively. These studies had not contributed to previous GWA studies and so our study provides completely independent replication of an apparently paradoxical association – alleles associated with higher fat mass lower the risk of metabolic disease. Our analyses separated by sex provided further insight into the likely mechanisms underlying these apparently paradoxical associations. In women, the extra body fat conferred by the favorable adiposity genetic score was more likely to be in the lower body, as measured by a lower waist-hip ratio and especially larger hip circumference. In men however, the extra body fat conferred by the favorable adiposity genetic score was more likely to be in the upper body, as indicated by a higher waist circumference and waist-hip ratio. Data from previous studies provides some further explanation for the apparently paradoxical association. For example, in combination, the favorable adiposity alleles are associated with higher subcutaneous to visceral adipose ratio (10) higher insulin sensitivity, higher hip circumference, and higher gynoid and leg fat mass (11). This set of associations is consistent with the alleles labeled as favorable adiposity (or most of them) exerting their effects through a primary role in adipose tissue and fat storage capacity, although we cannot rule out mechanisms where insulin resistance is the primary starting point.

Our data replicate previous associations but provide an important advance for several reasons. First, we provide further evidence that the “favorable adiposity” alleles are

associated predominantly with higher fat mass rather than any other aspect of BMI such as lean mass. This finding is consistent with previous studies (9-11) and important because it shows that the alleles associated with higher BMI are not protecting from disease through higher muscle mass. Instead our results confirm that the genetic score associated with lower disease risk is associated with higher adiposity. Second, our data of body fat mass and body fat percentage in 118,012 individuals indicate that the favourable adiposity effects are likely limited to seven of the eleven variants. Two of these variants, those in *IRS1* and *PPARG*, are well known and lie near genes with a well-established role in insulin signalling and adipocyte differentiation respectively. Our study shows that the variants in or near *LYPLAL1*, *PEPD*, *GRB14*, *ANKRD55*, and *FAM13A*, all of which were associated with body fat percentage at  $p < 3E-5$ , are very strong candidates for a role in adipocyte biology, an interpretation consistent with the fact that two of these variants, those in *LYPLAL1* and *GRB14*, were associated with waist hip ratio at genome wide significance in previous GWAS of waist-hip ratio (20). Third, we have quantified the effects of genetically higher BMI on disease in a very large population based study which means effects are relatively unbiased by disease ascertainment. Fourth, because we used a single very large population with individual level data available we were able to look for interactions between a genetic predisposition to higher BMI and favorable adiposity. We also found that the effects of the favorable adiposity variants on disease risk were similar across all bands of BMI. These interaction analyses, made feasible by the availability of individual level data in a single very large study, showed two things. First, that the favourable adiposity alleles reduce the risk of disease at all BMIs and at high and low genetic risk of obesity (based on alleles identified by the GIANT consortium). Second, that there is no evidence of a synergistic effect that means some individuals are at especially high or low genetic risk of adverse adiposity effects.

Our study had a number of limitations. First we do not know which molecular pathways lead to a favorable adiposity phenotype although the presence of variants near the *PPARG* and *IRS1* genes point to known mechanisms (21-23). Second, the 11 variants only explain a very small proportion of body fat percentage and disease risk. Many other factors will influence the difference in disease risk between two individuals of the same BMI. However, our results show that higher fat storage capacity is a likely mechanism that improves metabolic health in the general population. Third, the study of individual variants suggests that those at *ARL15* and *TET2* may not represent a favorable adiposity phenotype. The final variant, that in *RSPO3*, is associated with waist-hip ratio in previous GWAS studies and in the UK biobank (data not shown) but not with altered BMI or fat mass – and so may represent a simple redistribution of the same amount of body fat. The signal at *PDGFC* may have a very subtle effect and needs further investigation. A further limitation is that we have not examined whether or not the variants alter adipocyte cell size or related features of adipocyte “function” and future studies are needed to examine features of adipocytes in tissue biopsies from individuals carrying many favourable adiposity alleles.

In summary, the strong association between the favorable adiposity genetic score and body fat percentage and lower risk of cardiometabolic diseases regardless of BMI or high genetic predisposition to obesity suggests that the mechanism of disease protection is an increased capacity to store triglyceride subcutaneously. The explanation most compatible with our findings is that the increased adipose storage capacity is in the lower body in women, but the upper body in men. Individuals who have genetically higher fat storage capacity can stay metabolically healthier at higher BMIs than individuals without such genetic variation, thereby partially explaining the concept of individual BMI thresholds to develop metabolic disease.

**Author Contributions.** H.Y. and T.M.F conceived and designed the study. H.Y. analyzed the data, and wrote the first draft of the manuscript. H.Y., S.E.J., J.T., R.B., K.S.R., A.R.W., M.A.T., R.M.F., A.M., M.N.W. performed data processing in the UK biobank data. H.Y., T.M.F and A.H. (with EXTEND); L.L., R.A.S., C.L. and N.J.W. (with EPIC-Norfolk); R.A.J.S., S.P., J.W.J. and N.S. (with PROSPER); L.D. E.P. and C.C.P. (with GoDARTS); A.C. and C.H. (with Generation Scotland) performed statistical analysis/provided data. All co-authors commented on the manuscript and agreed with the manuscript results and conclusions.

T.M.F. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Acknowledgments.** The authors thank University of Exeter Medical School. EXTEND data were provided by the Peninsula Research Bank, part of the NIHR Exeter Clinical Research Facility.

**Funding.** S.E.J. is funded by the Medical Research Council (grant: MR/M005070/1). M.A.T., M.N.W. and A.M. are supported by the Wellcome Trust Institutional Strategic Support Award (WT097835MF). A.R.W. H.Y. and T.M.F. are supported by the European Research Council grant: 323195; SZ-245 50371-GLUCOSEGENES-FP7-IDEAS-ERC. R.M.F. is a Sir Henry Dale Fellow (Wellcome Trust and Royal Society grant: 104150/Z/14/Z). R.B. is funded by the Wellcome Trust and Royal Society grant: 104150/Z/14/Z. J.T. is funded by a Diabetes Research and Wellness Foundation Fellowship. A.T.H. is a Wellcome Trust Senior Investigator and a National Institute of Health Research senior investigator. The Wellcome Trust provides support for GoDARTS (awards 072960/z/03/z and 099177/z12/z). The PROSPER study was supported by an investigator initiated grant obtained from Bristol-Myers Squibb. Prof. Dr. J. W. Jukema is an Established



Clinical Investigator of the Netherlands Heart Foundation (grant 2001 D 032). Support for genotyping was provided by the seventh framework program of the European commission (grant 223004) and by the Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging grant 050-060-810). This work was performed as part of an ongoing collaboration of the PROSPER study group in the universities of Leiden, Glasgow and Cork. The research leading to these results has received funding from the Netherlands Consortium for Healthy Ageing (NCHA) and the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement n° HEALTH-F2-2009-223004 PHASE. The University of Edinburgh is a charitable body, registered in Scotland, with registration number SC005336. Generation Scotland received core funding from the Chief Scientist Office of the Scottish Government Health Directorate CZD/16/6 and the Scottish Funding Council HR03006. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, Edinburgh, Scotland and was funded by the UK's Medical Research Council and the Wellcome Trust. Ethics approval for the study was given by the NHS Tayside committee on research ethics (reference 05/S1401/89). EPIC-Norfolk was funded by the Medical Research Council MC\_UU\_12015/1 and MC\_PC\_13048. E.P. holds a Wellcome Trust New Investigator award (102820/Z/13/Z).

The funders had no influence on study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Duality of interests.** No potential conflicts of interest relevant to this article were reported.

### Figure legends

**Figure 1.** The effect of favourable adiposity on measures of adiposity and cardiometabolic disease risk in the UK Biobank study. Effects are given by comparing the 50% of people carrying the most favourable adiposity alleles with the 50% of people carrying the fewest favourable adiposity alleles. The error bars indicate 95% confidence intervals. All models were adjusted for age, sex, genotyping array, study center and within UK principle components.

**Figure 2.** The effect of favourable adiposity on measures of body distribution including waist circumference, hip circumference and waist-hip ratio separated by sex. Effects are per additional weighted copy of the adiposity increasing allele. All models were adjusted for age, sex, genotyping array, study center and principle components where applicable.

**Figure 3.** The effect of favourable adiposity on measures of adiposity and cardiometabolic disease risk in the UK Biobank study in all individuals and in individuals split into BMI categories. Effects are given by comparing the 50% of people carrying the most favourable adiposity alleles with the 50% of people carrying the fewest favourable adiposity alleles in all individuals and within BMI strata. The error bars indicate 95% confidence intervals. All models were adjusted for age, sex, genotyping array, study center and within UK principle components.

**Figure 4.** The combined effect of favorable adiposity and BMI genetic scores on cardiometabolic disease risk. We grouped the UK Biobank individuals based on the median of the two genetic score distributions: (i) low BMI – high FA: individuals with below median BMI genetic score and above median favorable adiposity genetic score, (ii) low BMI – low FA: individuals with below median BMI genetic score and below median favorable adiposity genetic score, (iii) high BMI – high FA: individuals with above median BMI genetic score

and above median favorable adiposity genetic score and (iv) high BMI – low FA: individuals with above median BMI genetic score and below median favorable adiposity genetic score.

The error bars indicate 95% confidence intervals.

**Table 1.** The effect of a favourable adiposity genetic score on measures of adiposity and cardiometabolic disease risk in the UK Biobank study. Effects are given per carrying additional adiposity increasing weighted allele. LCI: Lower confidence interval; UCI: Upper confidence interval; P: p-value; N: total sample size.

Outcome	Effect size	LCI	UCI	P	N
Body fat percentage (%)	0.126	0.104	0.149	8E-28	118,012
BMI (Kg/m <sup>2</sup> )	0.046	0.029	0.063	2E-7	119,688
Body fat mass (Kg)	0.156	0.123	0.190	3E-18	118,024
Body fat-free mass (Kg)	-0.030	-0.053	-0.007	0.01	118,221
Height (cm)	0.006	-0.017	0.028	0.6	120,084
Type 2 diabetes (OR)	0.943	0.924	0.963	2E-8	4,003 vs. 113,203
Systolic blood pressure (mmHg)	-0.255	-0.334	-0.176	2E-10	120,008
Diastolic blood pressure (mmHg)	-0.096	-0.143	-0.048	7E-5	119,821
Hypertension (OR)	0.982	0.974	0.989	3E-6	65,584 vs. 53,377
Heart disease (OR)	0.967	0.950	0.984	1E-4	5,758 vs. 113,930

## References

1. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S: The metabolically obese, normal-weight individual revisited. *Diabetes* 1998;47:699-713
2. Ruderman NB, Schneider SH, Berchtold P: The "metabolically-obese," normal-weight individual. *The American journal of clinical nutrition* 1981;34:1617-1621
3. Virtue S, Vidal-Puig A: Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective. *Biochimica et biophysica acta* 2010;1801:338-349
4. Semple RK, Chatterjee VK, O'Rahilly S: PPAR gamma and human metabolic disease. *The Journal of clinical investigation* 2006;116:581-589
5. Weedon MN, Ellard S, Prindle MJ, Caswell R, Lango Allen H, Oram R, Godbole K, Yajnik CS, Sbraccia P, Novelli G, Turnpenny P, McCann E, Goh KJ, Wang Y, Fulford J, McCulloch LJ, Savage DB, O'Rahilly S, Kos K, Loeb LA, Semple RK, Hattersley AT: An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. *Nature genetics* 2013;45:947-950
6. Fall T, Hagg S, Magi R, Ploner A, Fischer K, Horikoshi M, Sarin AP, Thorleifsson G, Ladenvall C, Kals M, Kuningas M, Draisma HH, Ried JS, van Zuydam NR, Huikari V, Mangino M, Sonestedt E, Benyamin B, Nelson CP, Rivera NV, Kristiansson K, Shen HY, Havulinna AS, Dehghan A, Donnelly LA, Kaakinen M, Nuotio ML, Robertson N, de Bruijn RF, Ikram MA, Amin N, Balmforth AJ, Braund PS, Doney AS, Doring A, Elliott P, Esko T, Franco OH, Gretarsdottir S, Hartikainen AL, Heikkila K, Herzig KH, Holm H, Hottenga JJ, Hypponen E, Illig T, Isaacs A, Isomaa B, Karssen LC, Kettunen J, Koenig W, Kuulasmaa K, Laatikainen T, Laitinen J, Lindgren C, Lyssenko V, Laara E, Rayner NW, Mannisto S, Pouta A, Rathmann W, Rivadeneira F, Ruukonen A, Savolainen MJ, Sijbrands EJ, Small KS, Smit JH, Steinthorsdottir V, Syvanen AC, Taanila A, Tobin MD, Uitterlinden AG, Willems SM, Willemsen G, Witteman J, Perola M, Evans A, Ferrieres J, Virtamo J, Kee F, Tregouet DA, Arveiler D, Amouyel P, Ferrario MM, Brambilla P, Hall AS, Heath AC, Madden PA, Martin NG, Montgomery GW, Whitfield JB, Jula A, Knekt P, Oostra B, van Duijn CM, Penninx BW, Smith GD, Kaprio J, Samani NJ, Gieger C, Peters A, Wichmann HE, Boomsma DI, de Geus EJ, Tuomi T, Power C, Hammond CJ, Spector TD, Lind L, Orho-Melander M, Palmer CN, Morris AD, Groop L, Jarvelin MR, Salomaa V, Vartiainen E, Hofman A, Ripatti S, Metspalu A, Thorsteinsdottir U, Stefansson K, Pedersen NL, McCarthy MI, Ingelsson E, Prokopenko I: The role of adiposity in cardiometabolic traits: a Mendelian randomization analysis. *PLoS medicine* 2013;10:e1001474
7. Nordestgaard BG, Palmer TM, Benn M, Zacho J, Tybjaerg-Hansen A, Davey Smith G, Timpson NJ: The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. *PLoS medicine* 2012;9:e1001212
8. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, Magi R, Strawbridge RJ, Rehnberg E, Gustafsson S, Kanoni S, Rasmussen-Torvik LJ, Yengo L, Lecoeur C, Shungin D, Sanna S, Sidore C, Johnson PC, Jukema JW, Johnson T, Mahajan A, Verweij N, Thorleifsson G, Hottenga JJ, Shah S, Smith AV, Sennblad B, Gieger C, Salo P, Perola M, Timpson NJ, Evans DM, Pourcain BS, Wu Y, Andrews JS, Hui J, Bielak LF, Zhao W, Horikoshi M, Navarro P, Isaacs A, O'Connell JR, Stirrups K, Vitart V, Hayward C, Esko T, Mihailov E, Fraser RM, Fall T, Voight BF, Raychaudhuri S, Chen H, Lindgren CM, Morris AP, Rayner NW, Robertson N, Rybin D, Liu CT, Beckmann JS, Willems SM, Chines PS, Jackson AU, Kang HM, Stringham HM, Song K, Tanaka T, Peden JF, Goel A, Hicks AA, An P, Muller-Nurasyid M, Franco-Cereceda A, Folkersen L, Marullo L, Jansen H, Oldehinkel AJ, Bruinenberg M, Pankow JS, North KE, Forouhi NG, Loos RJ, Edkins S, Varga TV, Hallmans G, Oksa H, Antonella M, Nagaraja R, Trompet S, Ford I, Bakker SJ, Kong A, Kumari M, Gigante B, Herder C, Munroe PB, Caulfield M, Antti J, Mangino M, Small K, Miljkovic I, Liu Y, Atalay M, Kiess W, James AL, Rivadeneira F, Uitterlinden AG, Palmer CN, Doney AS, Willemsen G, Smit JH, Campbell S, Polasek O, Bonnycastle LL, Hercberg S, Dimitriou M, Bolton JL, Fowkes GR, Kovacs P, Lindstrom J, Zemunik T, Bandinelli S, Wild SH, Basart HV, Rathmann W, Grallert H, Maerz W, Kleber ME, Boehm BO, Peters A, Pramstaller PP, Province MA, Borecki IB, Hastie ND, Rudan I, Campbell H, Watkins H, Farrall M, Stumvoll M, Ferrucci L, Waterworth DM, Bergman RN, Collins FS, Tuomilehto J, Watanabe RM, de Geus EJ, Penninx BW, Hofman A, Oostra BA,

Psaty BM, Vollenweider P, Wilson JF, Wright AF, Hovingh GK, Metspalu A, Uusitupa M, Magnusson PK, Kyvik KO, Kaprio J, Price JF, Dedoussis GV, Deloukas P, Meneton P, Lind L, Boehnke M, Shuldiner AR, van Duijn CM, Morris AD, Toenjes A, Peyser PA, Beilby JP, Korner A, Kuusisto J, Laakso M, Bornstein SR, Schwarz PE, Lakka TA, Rauramaa R, Adair LS, Smith GD, Spector TD, Illig T, de Faire U, Hamsten A, Gudnason V, Kivimaki M, Hingorani A, Keinanen-Kiukaanniemi SM, Saaristo TE, Boomsma DI, Stefansson K, van der Harst P, Dupuis J, Pedersen NL, Sattar N, Harris TB, Cucca F, Ripatti S, Salomaa V, Mohlke KL, Balkau B, Froguel P, Pouta A, Jarvelin MR, Wareham NJ, Bouatia-Naji N, McCarthy MI, Franks PW, Meigs JB, Teslovich TM, Florez JC, Langenberg C, Ingelsson E, Prokopenko I, Barroso I: Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. *Nature genetics* 2012;44:991-1005

9. Kilpelainen TO, Zillikens MC, Stancakova A, Finucane FM, Ried JS, Langenberg C, Zhang W, Beckmann JS, Luan J, Vandenput L, Styrkarsdottir U, Zhou Y, Smith AV, Zhao JH, Amin N, Vedantam S, Shin SY, Haritunians T, Fu M, Feitosa MF, Kumari M, Halldorsson BV, Tikkanen E, Mangino M, Hayward C, Song C, Arnold AM, Aulchenko YS, Oostra BA, Campbell H, Cupples LA, Davis KE, Doring A, Eiriksdottir G, Estrada K, Fernandez-Real JM, Garcia M, Gieger C, Glazer NL, Guiducci C, Hofman A, Humphries SE, Isomaa B, Jacobs LC, Jula A, Karasik D, Karlsson MK, Khaw KT, Kim LJ, Kivimaki M, Klopp N, Kuhnel B, Kuusisto J, Liu Y, Ljunggren O, Lorentzon M, Luben RN, McKnight B, Mellstrom D, Mitchell BD, Mooser V, Moreno JM, Mannisto S, O'Connell JR, Pascoe L, Peltonen L, Peral B, Perola M, Psaty BM, Salomaa V, Savage DB, Semple RK, Skaric-Juric T, Sigurdsson G, Song KS, Spector TD, Syvanen AC, Talmud PJ, Thorleifsson G, Thorsteinsdottir U, Uitterlinden AG, van Duijn CM, Vidal-Puig A, Wild SH, Wright AF, Clegg DJ, Schadt E, Wilson JF, Rudan I, Ripatti S, Borecki IB, Shuldiner AR, Ingelsson E, Jansson JO, Kaplan RC, Gudnason V, Harris TB, Groop L, Kiel DP, Rivadeneira F, Walker M, Barroso I, Vollenweider P, Waeber G, Chambers JC, Kooner JS, Soranzo N, Hirschhorn JN, Stefansson K, Wichmann HE, Ohlsson C, O'Rahilly S, Wareham NJ, Speliotes EK, Fox CS, Laakso M, Loos RJ: Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. *Nature genetics* 2011;43:753-760

10. Yaghootkar H, Scott RA, White CC, Zhang W, Speliotes E, Munroe PB, Ehret GB, Bis JC, Fox CS, Walker M, Borecki IB, Knowles JW, Yerges-Armstrong L, Ohlsson C, Perry JR, Chambers JC, Kooner JS, Franceschini N, Langenberg C, Hivert MF, Dastani Z, Richards JB, Semple RK, Frayling TM: Genetic evidence for a normal-weight "metabolically obese" phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes. *Diabetes* 2014;63:4369-4377

11. Scott RA, Fall T, Pasko D, Barker A, Sharp SJ, Arriola L, Balkau B, Barricarte A, Barroso I, Boeing H, Clavel-Chapelon F, Crowe FL, Dekker JM, Fagherazzi G, Ferrannini E, Forouhi NG, Franks PW, Gavrila D, Giedraitis V, Grioni S, Groop LC, Kaaks R, Key TJ, Kuhn T, Lotta LA, Nilsson PM, Overvad K, Palli D, Panico S, Quiros JR, Rolandsson O, Roswall N, Sacerdote C, Sala N, Sanchez MJ, Schulze MB, Siddiq A, Slimani N, Sluijs I, Spijkerman AM, Tjonneland A, Tumino R, van der AD, Yaghootkar H, McCarthy MI, Semple RK, Riboli E, Walker M, Ingelsson E, Frayling TM, Savage DB, Langenberg C, Wareham NJ: Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity. *Diabetes* 2014;63:4378-4387

12. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, Croteau-Chonka DC, Esko T, Fall T, Ferreira T, Gustafsson S, Kutalik Z, Luan J, Magi R, Randall JC, Winkler TW, Wood AR, Workalemahu T, Faul JD, Smith JA, Hua Zhao J, Zhao W, Chen J, Fehrmann R, Hedman AK, Karjalainen J, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bolton JL, Bragg-Gresham JL, Buyske S, Demirkan A, Deng G, Ehret GB, Feenstra B, Feitosa MF, Fischer K, Goel A, Gong J, Jackson AU, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Mangino M, Mateo Leach I, Medina-Gomez C, Medland SE, Nalls MA, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Shungin D, Stancakova A, Strawbridge RJ, Ju Sung Y, Tanaka T, Teumer A, Trompet S, van der Laan SW, van Setten J, Van Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Isaacs A, Albrecht E, Arnlöv J, Arscott GM, Attwood AP, Bandinelli S, Barrett A, Bas IN, Bellis C, Bennett AJ, Berne C, Blagieva R, Bluher M, Bohringer S, Bonnycastle LL, Bottcher Y, Boyd HA, Bruinenberg M, Caspersen IH, Ida Chen YD, Clarke R, Daw EW, de Craen AJ, Delgado G, Dimitriou M, Doney AS,

Eklund N, Estrada K, Eury E, Folkersen L, Fraser RM, Garcia ME, Geller F, Giedraitis V, Gigante B, Go AS, Golay A, Goodall AH, Gordon SD, Gorski M, Grabe HJ, Grallert H, Grammer TB, Grassler J, Gronberg H, Groves CJ, Gusto G, Haessler J, Hall P, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward C, Heard-Costa NL, Helmer Q, Hengstenberg C, Holmen O, Hottenga JJ, James AL, Jeff JM, Johansson A, Jolley J, Juliusdottir T, Kinnunen L, Koenig W, Koskenvuo M, Kratzer W, Laitinen J, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindstrom J, Sin Lo K, Lobbens S, Lorbeer R, Lu Y, Mach F, Magnusson PK, Mahajan A, McArdle WL, McLachlan S, Menni C, Merger S, Mihailov E, Milani L, Moayyeri A, Monda KL, Morken MA, Mulas A, Muller G, Muller-Nurasyid M, Musk AW, Nagaraja R, Nothen MM, Nolte IM, Pilz S, Rayner NW, Renstrom F, Rettig R, Ried JS, Ripke S, Robertson NR, Rose LM, Sanna S, Scharnagl H, Scholtens S, Schumacher FR, Scott WR, Seufferlein T, Shi J, Vernon Smith A, Smolonska J, Stanton AV, Steinthorsdottir V, Stirrups K, Stringham HM, Sundstrom J, Swertz MA, Swift AJ, Syvanen AC, Tan ST, Tayo BO, Thorand B, Thorleifsson G, Tyrer JP, Uh HW, Vandenput L, Verhulst FC, Vermeulen SH, Verweij N, Vonk JM, Waite LL, Warren HR, Waterworth D, Weedon MN, Wilkens LR, Willenborg C, Wilsgaard T, Wojczynski MK, Wong A, Wright AF, Zhang Q, Brennan EP, Choi M, Dastani Z, Drong AW, Eriksson P, Franco-Cereceda A, Gadin JR, Gharavi AG, Goddard ME, Handsaker RE, Huang J, Karpe F, Kathiresan S, Keildson S, Kiryluk K, Kubo M, Lee JY, Liang L, Lifton RP, Ma B, McCarroll SA, McKnight AJ, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Okada Y, Perry JR, Dorajoo R, Reinmaa E, Salem RM, Sandholm N, Scott RA, Stolk L, Takahashi A, Tanaka T, Van't Hooft FM, Vinkhuyzen AA, Westra HJ, Zheng W, Zondervan KT, Heath AC, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Blangero J, Bovet P, Campbell H, Caulfield MJ, Cesana G, Chakravarti A, Chasman DI, Chines PS, Collins FS, Crawford DC, Cupples LA, Cusi D, Danesh J, de Faire U, den Ruijter HM, Dominiczak AF, Erbel R, Erdmann J, Eriksson JG, Farrall M, Felix SB, Ferrannini E, Ferrieres J, Ford I, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gejman PV, Gieger C, Gottesman O, Gudnason V, Gyllenstein U, Hall AS, Harris TB, Hattersley AT, Hicks AA, Hindorff LA, Hingorani AD, Hofman A, Homuth G, Hovingh GK, Humphries SE, Hunt SC, Hypponen E, Illig T, Jacobs KB, Jarvelin MR, Jockel KH, Johansen B, Jousilahti P, Jukema JW, Jula AM, Kaprio J, Kastelein JJ, Keinänen-Kiukaanniemi SM, Kiemenev LA, Knekt P, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimäki T, Lyssenko V, Mannisto S, Marette A, Matise TC, McKenzie CA, McKnight B, Moll FL, Morris AD, Morris AP, Murray JC, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Madden PA, Pasterkamp G, Peden JF, Peters A, Postma DS, Pramstaller PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Rioux JD, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schunkert H, Schwarz PE, Sever P, Shuldiner AR, Sinisalo J, Stolk RP, Strauch K, Tonjes A, Tregouet DA, Tremblay A, Tremoli E, Virtamo J, Vohl MC, Volker U, Waeber G, Willemssen G, Witteman JC, Zillikens MC, Adair LS, Amouyel P, Asselbergs FW, Assimes TL, Bochud M, Boehm BO, Boerwinkle E, Bornstein SR, Bottinger EP, Bouchard C, Cauchi S, Chambers JC, Chanock SJ, Cooper RS, de Bakker PI, Dedoussis G, Ferrucci L, Franks PW, Froguel P, Groop LC, Haiman CA, Hamsten A, Hui J, Hunter DJ, Hveem K, Kaplan RC, Kivimäki M, Kuh D, Laakso M, Liu Y, Martin NG, Marz W, Melbye M, Metspalu A, Moebus S, Munroe PB, Njolstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Perusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sattar N, Schadt EE, Schlessinger D, Slagboom PE, Snieder H, Spector TD, Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Walker M, Wallaschofski H, Wareham NJ, Watkins H, Weir DR, Wichmann HE, Wilson JF, Zanen P, Borecki IB, Deloukas P, Fox CS, Heid IM, O'Connell JR, Strachan DP, Stefansson K, van Duijn CM, Abecasis GR, Franke L, Frayling TM, McCarthy MI, Visscher PM, Scherag A, Willer CJ, Boehnke M, Mohlke KL, Lindgren CM, Beckmann JS, Barroso I, North KE, Ingelsson E, Hirschhorn JN, Loos RJ, Speliotes EK: Genetic studies of body mass index yield new insights for obesity biology. *Nature* 2015;518:197-206

13. Collins R: What makes UK Biobank special? *Lancet* (London, England) 2012;379:1173-1174

14. Abraham G, Inouye M: Fast principal component analysis of large-scale genome-wide data. *PLoS one* 2014;9:e93766

15. Morris AD, Boyle DI, McMahon AD, Greene SA, MacDonald TM, Newton RW: Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. *Lancet* (London, England) 1997;350:1505-1510
16. Smith BH, Campbell A, Linksted P, Fitzpatrick B, Jackson C, Kerr SM, Deary IJ, Macintyre DJ, Campbell H, McGilchrist M, Hocking LJ, Wisely L, Ford I, Lindsay RS, Morton R, Palmer CN, Dominiczak AF, Porteous DJ, Morris AD: Cohort Profile: Generation Scotland: Scottish Family Health Study (GS:SFHS). The study, its participants and their potential for genetic research on health and illness. *International journal of epidemiology* 2013;42:689-700
17. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* (London, England) 2002;360:1623-1630
18. Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, Ford I, Jukema JW, Hyland M, Gaw A, Lagaay AM, Perry IJ, Macfarlane PW, Meinders AE, Sweeney BJ, Packard CJ, Westendorp RG, Twomey C, Stott DJ: The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. *The American journal of cardiology* 1999;84:1192-1197
19. Bingham S, Riboli E: Diet and cancer--the European Prospective Investigation into Cancer and Nutrition. *Nature reviews Cancer* 2004;4:206-215
20. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, Strawbridge RJ, Pers TH, Fischer K, Justice AE, Workalemahu T, Wu JM, Buchkovich ML, Heard-Costa NL, Roman TS, Drong AW, Song C, Gustafsson S, Day FR, Esko T, Fall T, Kutalik Z, Luan J, Randall JC, Scherag A, Vedantam S, Wood AR, Chen J, Fehrmann R, Karjalainen J, Kahali B, Liu CT, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bragg-Gresham JL, Buyske S, Demirkan A, Ehret GB, Feitosa MF, Goel A, Jackson AU, Johnson T, Kleber ME, Kristiansson K, Mangino M, Mateo Leach I, Medina-Gomez C, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Stancakova A, Ju Sung Y, Tanaka T, Teumer A, Van Vliet-Ostaptchouk JV, Yengo L, Zhang W, Albrecht E, Arnlöv J, Arscott GM, Bandinelli S, Barrett A, Bellis C, Bennett AJ, Berne C, Bluher M, Bohringer S, Bonnet F, Bottcher Y, Bruinenberg M, Carba DB, Caspersen IH, Clarke R, Daw EW, Deelen J, Deelman E, Delgado G, Doney AS, Eklund N, Erdos MR, Estrada K, Eury E, Friedrich N, Garcia ME, Giedraitis V, Gigante B, Go AS, Golay A, Grallert H, Grammer TB, Grassler J, Grewal J, Groves CJ, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward C, Heikkila K, Herzig KH, Helmer Q, Hillege HL, Holmen O, Hunt SC, Isaacs A, Ittermann T, James AL, Johansson I, Juliusdottir T, Kalafati IP, Kinnunen L, Koenig W, Kooner IK, Kratzer W, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindstrom J, Lobbens S, Lorentzon M, Mach F, Magnusson PK, Mahajan A, McArdle WL, Menni C, Merger S, Mihailov E, Milani L, Mills R, Moayyeri A, Monda KL, Mooijart SP, Muhleisen TW, Mulas A, Muller G, Muller-Nurasyid M, Nagaraja R, Nalls MA, Narisu N, Glorioso N, Nolte IM, Olden M, Rayner NW, Renstrom F, Ried JS, Robertson NR, Rose LM, Sanna S, Scharnagl H, Scholtens S, Sennblad B, Seufferlein T, Sitlani CM, Vernon Smith A, Stirrups K, Stringham HM, Sundstrom J, Swertz MA, Swift AJ, Syvanen AC, Tayo BO, Thorand B, Thorleifsson G, Tomaschitz A, Troffa C, van Oort FV, Verweij N, Vonk JM, Waite LL, Wennauer R, Wilsgaard T, Wojczynski MK, Wong A, Zhang Q, Hua Zhao J, Brennan EP, Choi M, Eriksson P, Folkersen L, Franco-Cereceda A, Gharavi AG, Hedman AK, Hivert MF, Huang J, Kanoni S, Karpe F, Keildson S, Kiryluk K, Liang L, Lifton RP, Ma B, McKnight AJ, McPherson R, Metspalu A, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Olsson C, Perry JR, Reinmaa E, Salem RM, Sandholm N, Schadt EE, Scott RA, Stolk L, Vallejo EE, Westra HJ, Zondervan KT, Amouyel P, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Blangero J, Brown MJ, Burnier M, Campbell H, Chakravarti A, Chines PS, Claudi-Boehm S, Collins FS, Crawford DC, Danesh J, de Faire U, de Geus EJ, Dorr M, Erbel R, Eriksson JG, Farrall M, Ferrannini E, Ferrieres J, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gieger C, Gudnason V, Haiman CA, Harris TB, Hattersley AT, Heliovaara M, Hicks AA, Hingorani AD, Hoffmann W, Hofman A, Homuth G, Humphries SE, Hypponen E, Illig T, Jarvelin MR, Johansen B, Jousilahti P, Jula AM, Kaprio J, Kee F,









Keinanen-Kiukaanniemi SM, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuulasmaa K, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimäki T, Lyssenko V, Mannisto S, Marette A, Matise TC, McKenzie CA, McKnight B, Musk AW, Mohlenkamp S, Morris AD, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Palmer LJ, Penninx BW, Peters A, Pramstaller PP, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schwarz PE, Shuldiner AR, Staessen JA, Steinthorsdottir V, Stolk RP, Strauch K, Tonjes A, Tremblay A, Tremoli E, Vohl MC, Volker U, Vollenweider P, Wilson JF, Witteman JC, Adair LS, Bochud M, Boehm BO, Bornstein SR, Bouchard C, Cauchi S, Caulfield MJ, Chambers JC, Chasman DI, Cooper RS, Dedoussis G, Ferrucci L, Froguel P, Grabe HJ, Hamsten A, Hui J, Hveem K, Jockel KH, Kivimäki M, Kuh D, Laakso M, Liu Y, Marz W, Munroe PB, Njolstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Perusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sinisalo J, Slagboom PE, Snieder H, Spector TD, Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Veronesi G, Walker M, Wareham NJ, Watkins H, Wichmann HE, Abecasis GR, Assimes TL, Berndt SI, Boehnke M, Borecki IB, Deloukas P, Franke L, Frayling TM, Groop LC, Hunter DJ, Kaplan RC, O'Connell JR, Qi L, Schlessinger D, Strachan DP, Stefansson K, van Duijn CM, Willer CJ, Visscher PM, Yang J, Hirschhorn JN, Zillikens MC, McCarthy MI, Speliotes EK, North KE, Fox CS, Barroso I, Franks PW, Ingelsson E, Heid IM, Loos RJ, Cupples LA, Morris AP, Lindgren CM, Mohlke KL: New genetic loci link adipose and insulin biology to body fat distribution. *Nature* 2015;518:187-196

21. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM: PPAR gamma is required for placental, cardiac, and adipose tissue development. *Molecular cell* 1999;4:585-595

22. Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M, Curtis RK, Jimenez-Linan M, Blount M, Yeo GS, Lopez M, Seppanen-Laakso T, Ashcroft FM, Oresic M, Vidal-Puig A: PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. *PLoS genetics* 2007;3:e64

23. Tseng YH, Kriauciunas KM, Kokkottou E, Kahn CR: Differential roles of insulin receptor substrates in brown adipocyte differentiation. *Molecular and cellular biology* 2004;24:1918-1929





- Men**
- UK Biobank
  - Gen Scotland
  - EXTEND
  - EPIC
- Women**
- UK Biobank
  - Gen Scotland
  - EXTEND
  - EPIC




Figure 3





Figure 4  
Page 37 of 58



**Table S1.** Summary characteristics of participating studies.

Variable	Statistics	UK Biobank	EXTEND	Generation Scotland	GoDARTS	PROSPER	EPIC-Norfolk
<b>Age</b>	<b>N</b> <b>mean [min to max] (sd)</b>	120286 56.92 [40 to 73] (7.94)	6504 56.51 [18 to 98 ] (15.11)	14064 48.58 [18 to 99] (15.07)	4086 60.23 [30.78 to 92.28] (11.45)	5244 75.34 [70 to 83.39] (3.35)	20855 59.15 [39.49 to 79.08] (9.27)
<b>Sex</b>	<b>males / females</b>	56936 / 63350	2772 / 3732	5784 / 8280	2107 / 1979	2524 / 2720	9,699 / 11,156
<b>BMI (kg m-2)</b>	<b>N</b> <b>mean [min to max] (sd)</b>	119688 27.53 [12.12 to 74.68] (4.82)	6493 27.34 [14.27 to 63.37 ] (5.22)	13968 26.87 [13.16 to 71.35] (5.42)	4085 27.44 [14.3 to 59.8] (4.79)	5244 26.82 [15.24 to 50.08] (4.18)	20825 26.29 [15.23 to 58.70] (3.82)
<b>Body fat percentage</b>	<b>N</b> <b>mean [min to max] (sd)</b>	118012 31.44 [6.92 to 69.79] (8.5)	5969 31.83 [1.2 to 58 ] (8.67)	13668 30.23 [1 to 62] (9.68)	NA	NA	13422 32.34 [1.5 to 98.5] (11.19)
<b>Type 2 diabetes</b>	<b>N cases / N controls</b>	4040 / 113735	1505 / 5444	477 / 13551	327 / 3759	544 / 4700	1,347 / 19,508
<b>Systolic blood pressure (mmHg)</b>	<b>N</b> <b>mean [min to max] (sd)</b>	120008 144.87 [72 to 252.5] (24.13)	6503 136.07 [84 to 234 ] (20.89)	14041 133.25 [74 to 239] (19.27)	4081 142.27 [85 to 237.5] (22.36)	5220 163.66 [76 to 235] (24.05)	20817 138.05 [88 to 235] (20.09)
<b>Diastolic blood pressure (mmHg)</b>	<b>N</b> <b>mean [min to max] (sd)</b>	119821 86.65 [40 to 147] (13.58)	6503 79.57 [47 to 131 ] (11.19)	14041 80.58 [42 to 145] (10.98)	4081 83.64 [46.5 to 129.5] (11.07)	5220 89.65 [47 to 129] (12.8)	20817 84.32 [46.5 to 189] (12.18)
<b>Hypertension</b>	<b>N cases / N controls</b>	65,976 / 53,567	1718 / 5460	2056 / 11972	1774 / 2307	3257 / 1987	9,449 / 11,406
<b>Heart disease</b>	<b>N cases / N controls</b>	5807 / 114479	509 / 6669	571 / 13457	NA	2034 / 3210	1,369 / 19,486
<b>PLD risk score</b>	<b>N</b> <b>mean [min to max] (sd)</b>	120286 9.77 [2.91 to 15.45] (1.57)	6268 9.32 [2 to 13.94 ] (1.51)	8226 10.22 [3.82 to 15.45] (1.52)	4086 9.76 [4.23 to 14.56] (1.61)	5244 9.79 [4.25 to 14.82] (1.57)	20855 9.77 [3.62 to 15.34] (1.58)

**Table S2.** Eleven variants associated with favorable adiposity. Weights are from the most recent meta-analysis of Glucose and Insulin Consortium (MAGIC) genome wide association studies normalized based on the variant at *PPARG*. The genotype information is for the UK Biobank study. MAF: Minor allele frequency.

SNP	Notable gene(s)	MAF	Adiposity increasing allele	Other allele	Directly genotyped/imputed	Imputation r2	Weights
rs459193	<i>ANKRD55-MAP3K1</i>	0.27	A	G	imputed	1.00	0.69
rs4865796	<i>ARL15</i>	0.33	G	A	imputed	1.00	0.73
rs3822072	<i>FAM13A</i>	0.48	G	A	imputed	1.00	0.55
rs10195252	<i>GRB14</i>	0.40	C	T	imputed	1.00	0.82
rs2943645	<i>IRS1</i>	0.37	C	T	imputed	1.00	0.91
rs4846565	<i>LYPLAL1</i>	0.33	A	G	imputed	1.00	0.62
rs6822892	<i>PDGFC</i>	0.32	G	A	imputed	1.00	0.65
rs731839	<i>PEPD</i>	0.34	A	G	imputed	1.00	0.7
rs17036328	<i>PPARG</i>	0.14	C	T	imputed	1.00	1
rs2745353	<i>RSPO3</i>	0.49	C	T	imputed	1.00	0.67
rs974801	<i>TET2</i>	0.38	A	G	imputed	1.00	0.66



**Table S3.** Genetic variant previously identified to be associated with BMI in genome wide association studies. The genotype information is for the UK Biobank study.

SNP	Notable gene(s)	Excluded	Reason for exclusion	BMI increasing allele	Other allele	Directly genotyped/imputed	Imputation r2
rs1000940	<i>RABEP1</i>	No	NA	G	A	Imputed	1.00
rs10132280	<i>STXBP6</i>	No	NA	C	A	Imputed	0.97
rs1016287	<i>FLJ30838</i>	No	NA	T	C	Imputed	0.99
rs10182181	<i>ADCY3</i>	No	NA	G	A	Imputed	1.00
rs10733682	<i>LMX1B</i>	No	NA	A	G	Imputed	0.96
rs10938397	<i>GNPDA2</i>	No	NA	G	A	Directly genotyped	NA
rs10968576	<i>LINGO2</i>	No	NA	G	A	Directly genotyped	NA
rs11030104	<i>BDNF</i>	Yes	BMI-raising allele also associated with regular smoking (which itself has a causal effect on BMI in opposite direction)	A	G	NA	NA
rs11057405	<i>CLIP1</i>	No	NA	G	A	Directly genotyped	NA
rs11126666	<i>KCNK3</i>	No	NA	A	G	Imputed	0.99
rs11165643	<i>PTBP2</i>	No	NA	T	C	Imputed	1.00
rs11191560	<i>NT5C2</i>	No	NA	C	T	Imputed	1.00
rs11583200	<i>ELAVL4</i>	No	NA	C	T	Imputed	0.99
rs1167827	<i>HIP1</i>	No	SNP not in HWE	G	A	Directly genotyped	NA
rs11688816	<i>EHBP1</i>	No	NA	G	A	Imputed	0.98
rs11727676	<i>HHIP</i>	No	NA	T	C	Directly genotyped	NA
rs11847697	<i>PRKD1</i>	No	NA	T	C	Directly genotyped	NA
rs12286929	<i>CADM1</i>	No	NA	G	A	Imputed	0.99
rs12401738	<i>FUBP1</i>	No	NA	A	G	Imputed	1.00

rs12429545	OLFM4	No	NA	A	G	Imputed	0.98
rs12446632	GPRC5B	No	NA	G	A	Imputed	1.00
rs12566985	FPGT-TNNI3K	No	NA	G	A	Imputed	0.99
rs12885454	PRKD1	No	NA	C	A	Imputed	1.00
rs12940622	RPTOR	No	NA	G	A	Imputed	1.00
rs13021737	TMEM18	No	NA	G	A	Imputed	0.99
rs13078960	CADM2	No	NA	G	T	Imputed	0.99
rs13107325	SLC39A8	Yes	Missense Ala/Thr polymorphism located in exon 7 of SLC39A8, which encodes a zinc transporter that also transports cadmium and manganese. It is also associated with BP and HDL levels, and presumably these and the BMI effect are secondary to the metal ion transport variation.	T	C	NA	NA
rs13191362	PARK2	No	NA	A	G	Imputed	0.99
rs1516725	ETV5	No	NA	C	T	Imputed	0.99
rs1528435	UBE2E3	No	NA	T	C	Imputed	1.00
rs1558902	FTO	No	NA	A	T	Imputed	1.00
rs16851483	RASA2	No	NA	T	G	Imputed	1.00
rs16951275	MAP2K5	No	NA	T	C	Imputed	1.00
rs17001654	SCARB2	Yes	SNP not in HWE	G	C	NA	NA
rs17024393	GNAT2	No	NA	C	T	Imputed	0.99
rs17094222	HIF1AN	No	NA	C	T	Imputed	0.97
rs17405819	HNF4G	No	NA	T	C	Imputed	1.00

rs17724992	<i>PGPEP1</i>	No	NA	A	G	Imputed	0.98
rs1808579	<i>C18orf8</i>	No	NA	C	T	Imputed	1.00
rs1928295	<i>TLR4</i>	No	NA	T	C	Imputed	1.00
rs2033529	<i>TDRG1</i>	Yes	SNP not available	G	A	NA	NA
rs2033732	<i>RALYL</i>	No	NA	C	T	Directly genotyped	NA
rs205262	<i>C6orf106</i>	No	NA	G	A	Imputed	1.00
rs2075650	<i>TOMM40</i>	No	SNP not in HWE	A	G	Imputed	0.99
rs2112347	<i>POC5</i>	No	NA	T	G	Directly genotyped	NA
rs2121279	<i>LRP1B</i>	No	NA	T	C	Imputed	0.99
rs2176598	<i>HSD17B12</i>	No	NA	T	C	Directly genotyped	NA
rs2207139	<i>TFAP2B</i>	No	NA	G	A	Imputed	1.00
rs2245368	<i>PMS2L11</i>	No	NA	C	T	Directly genotyped	NA
rs2287019	<i>QPCTL</i>	No	NA	C	T	Imputed	0.98
rs2365389	<i>FHIT</i>	No	NA	C	T	Imputed	0.99
rs2650492	<i>SBK1</i>	No	NA	A	G	Imputed	0.98
rs2820292	<i>NAV1</i>	No	NA	C	A	Directly genotyped	NA
rs29941	<i>KCTD15</i>	No	NA	G	A	Directly genotyped	NA
rs3101336	<i>NEGR1</i>	No	NA	C	T	Directly genotyped	NA
rs3736485	<i>DMXL2</i>	No	NA	A	G	Imputed	0.99
rs3810291	<i>ZC3H4</i>	No	NA	A	G	Directly genotyped	NA
rs3817334	<i>MTCH2</i>	No	NA	T	C	Directly genotyped	NA
rs3849570	<i>GBE1</i>	No	NA	A	C	Imputed	1.00
rs3888190	<i>ATP2A1</i>	Yes	Associated with lots of other traits and is a big haplotype	A	C	NA	NA
rs4256980	<i>TRIM66</i>	No	NA	G	C	Imputed	0.99

rs4740619	C9orf93	No	NA	T	C	Imputed	1.00
rs543874	SEC16B	No	NA	G	A	Directly genotyped	NA
rs6477694	EPB41L4B	No	NA	C	T	Imputed	0.99
rs6567160	MC4R	No	NA	C	T	Imputed	1.00
rs657452	AGBL4	No	NA	A	G	Imputed	0.99
rs6804842	RARB	No	NA	G	A	Imputed	0.99
rs7138803	BCDIN3D	No	NA	A	G	Directly genotyped	NA
rs7141420	NRXN3	No	NA	T	C	Imputed	0.98
rs7243357	GRP	No	NA	T	G	Imputed	0.99
rs758747	NLRC3	No	NA	T	C	Imputed	0.97
rs7599312	ERBB4	No	NA	G	A	Imputed	0.97
rs7899106	GRID1	No	NA	G	A	Imputed	0.99
rs9400239	FOXO3	No	NA	C	T	Imputed	0.99
rs9581854	MTIF3	No	NA	T	C	Imputed	0.99
rs9925964	KAT8	No	NA	A	G	Directly genotyped	NA

**Table S4.** Details of genotyping/imputation methods used by each study.

	Which SNPs were directly genotyped?	Which SNPs were imputed?	Imputation software	Reference panel	Imputation Quality	Genotyping platform	Genotyping centre	Genotyping calling algorithm	Call rate	HWE
<b>EXTEND</b>	ALL	NA	NA	NA	NA	KASP	LGC, Queens Road, Teddington, Middlesex, TW11 0LY, UK	NA	> 99%	> 0.05
<b>Generation Scotland</b>	rs17367504, rs3753584, rs213765, rs1238, rs2932538, rs9425291, rs1044299, rs2605096, rs1572505, rs12999687, rs1260326, rs13408002, rs2540950, rs2249105, rs4988235, rs182549, rs7592412, rs3769877, rs2943645, rs2972143, rs6766610, rs9863261, rs160208, rs17036328, rs2197423,	rs633185, rs11953630, rs2521501, rs6912327, rs17169104, rs1725074, rs6581104, rs2710322, rs6061036, rs1530559, rs2822383, rs8129930, rs6574629, rs34106, rs6664203, rs12125782, rs9394279	SHAPEIT and IMPUTE2	1000G Version 3	RSQ>0.4	Illumina HumanOmniExpressExome-8v1_A	Edinburgh Wellcome Trust Clinical Research Facility	Genome Studio	>=0.98	>1e-6





[illegible]



	rs4598913, rs7192726, rs9939973, rs1121980, rs11078685, rs4925108, rs17608766, rs11874, rs12952581, rs12454712, rs4804833, rs731839, rs12481037, rs6072279, rs6026728, rs132985, rs133021									
<b>GoDARTS</b>	Combination of directly genotyped and imputed dosages for all variants.		NA	NA	NA	Affymetrics, Illumina	NA	NA	> 99%	> 0.001
<b>Table S5.</b> Association between 11 favorable adiposity variants and body fat percentage in the UK Biobank study. LCI: Lower confidence interval; UCI: Upper confidence interval; P: p-value; N: total sample size.										
<b>OUTCOME</b>		<b>LOGI</b>		<b>BETA</b>		<b>LCI</b>		<b>UCI</b>	<b>P</b>	<b>N</b>
<b>Body fat percentage</b>	rs17036528, rs3822072, rs6822892, rs4846565,	<b>LYPLAL1</b>		0.176	excellent, all	0.123		0.228	7E-11	118012
<b>Body fat percentage</b>	rs95252, rs2943645, rs974801	<b>PPARG</b> <b>PEPD</b>	MACH	0.251 0.142	Hapmap SNPs built II MACH Rsq > 0.95	0.174 0.094	Illumina 660-Quad beadchip	0.328 0.401	Erasmus MC, Rotterdam, the Netherlands 2E-10	118012 > 0.975
<b>Body fat percentage</b>		<b>GRB14</b>		0.128		0.077		0.180	9E-7	118012
<b>Body fat percentage</b>		<b>IRS1</b>		0.123		0.070		0.175	5E-6	118012
<b>Body fat percentage</b>		<b>ANKRD55</b>		0.125		0.067		0.183	2E-5	118012
<b>Body fat percentage</b>		<b>FAM13A</b>		0.108		0.057		0.158	E-5	118012

Body fat perce										
Body fat perce										
Body fat perce										
Body fat perce										
PROSPER										
EPIC	All but rs6536208	rs6536208	IMPUTE 2.3.1	1000 Genomes v3	NA	UKBiobank Axiom	U.CAM Pathology & Affymetrix	Axiom GT1	> 0.95	> 1E-8

**Table S6.** Association between the favorable adiposity genetic scores and waist-hip ratio, waist circumference and hip circumference in the UK Biobank study. LCI: Lower confidence interval; UCI: Upper confidence interval; P: p-value; N: total sample size.

Genetic score	Trait	Sex	Beta	LCI	UCI	P	N	P-heterogeneity between sexes
11 SNPs	Waist-hip ratio	All	-0.0006	-0.0009	-0.0004	1E-7	120095	3E-18
11 SNPs	Waist-hip ratio	Men	0.0005	0.0002	0.0009	0.001	56849	
11 SNPs	Waist-hip ratio	Women	-0.0017	-0.0021	-0.0014	9E-23	63246	
11 SNPs	Waist	All	0.0607	0.0175	0.1038	0.006	120121	1E-6
11 SNPs	Waist	Men	0.1726	0.1131	0.2320	1E-8	56865	
11 SNPs	Waist	Women	-0.0398	-0.1019	0.0223	0.2	63256	
11 SNPs	Hip	All	0.1400	0.1068	0.1733	2E-16	120112	0.2
11 SNPs	Hip	Men	0.1178	0.0776	0.1581	1E-8	56859	
11 SNPs	Hip	Women	0.1607	0.1090	0.2125	1E-9	63253	
7 SNPs	Waist-hip ratio	All	-0.0003	-0.0006	-2E-06	0.05	120095	7E-14
7 SNPs	Waist-hip ratio	Men	0.0009	0.0005	0.0014	5E-6	56849	
7 SNPs	Waist-hip ratio	Women	-0.0014	-0.0018	-0.0010	3E-11	63246	
7 SNPs	Waist	All	0.1251	0.0722	0.1779	4E-6	120121	0.0001

7 SNPs	Waist	Men	0.2346	0.1618	0.3073	3E-10	56865	0.09
7 SNPs	Waist	Women	0.0269	-0.0492	0.1031	0.5	63256	
7 SNPs	Hip	All	0.1728	0.1320	0.2135	9E-17	120112	
7 SNPs	Hip	Men	0.1374	0.0882	0.1867	5E-8	56859	
7 SNPs	Hip	Women	0.2060	0.1426	0.2694	2E-10	63253	

**Table S7.** The effect of the favorable adiposity genetic score on measures of adiposity and cardiometabolic disease risk. Results are from the meta-analysis of 6 studies. NA: not available; LCI: lower confidence interval; UCI: upper confidence interval. Effects are per additional weighted copy of the adiposity increasing allele.

TRAIT	BETA/OR	LCI	UCI	P	N	P-heterogeneity
Body fat percentage	0.124	0.103	0.145	8.00E-31	145,187	0.7
BMI	0.043	0.029	0.057	3 E-09	164,274	0.4
Type 2 diabetes	0.937	0.952	0.923	5.00E-17	6,735 vs. 155,253	0.6
Systolic blood pressure	-0.251	-0.315	-0.187	2.00E-14	164,609	0.9
Diastolic blood pressure	-0.107	-0.146	-0.068	7.00E-08	164,422	0.6
Hypertension	0.981	0.988	0.975	3.00E-08	82,512 vs. 81,239	0.5
Heart disease	0.973	0.987	0.96	1.00E-04	8,881 vs. 151,532	0.4

**Table S8.** The effect of favourable adiposity on measures of adiposity and cardiometabolic disease risk in the UK Biobank study. Effects are given by comparing the 50% of people carrying the most favourable adiposity alleles with the 50% of people carrying the fewest favourable adiposity alleles. NA: not available; LCI: lower confidence interval; UCI: upper confidence interval. Effects are per additional weighted copy of the adiposity increasing allele.

OUTCOME	BETA/OR	LCI	UCI	P
Body fat percentage	0.301	0.230	0.372	1E-16
BMI	0.120	0.066	0.174	0.00001
Body fat mass	0.397	0.291	0.503	2E-13
body fat-free mass	-0.036	-0.109	0.036	0.3
Type 2 diabetes	0.895	0.840	0.954	0.0006
Systolic blood pressure	-0.732	-0.980	-0.484	7E-9
Diastolic blood pressure	-0.292	-0.440	-0.144	0.0001
Hypertension	0.946	0.923	0.969	7E-6
Heart disease	0.942	0.892	0.994	0.03

**Table S9.** Within sex effect of 11 favorable adiposity genetic score on measures of adiposity and cardiometabolic disease risk in the UK Biobank study. Effects are per additional weighted copy of the adiposity increasing allele. LCI: Lower confidence interval; UCI: Upper confidence interval; P: p-value; N: total sample size.

	Men					Women					
OUTCOME	BETA/OR	LCI	UCI	P	N	BETA/OR	LCI	UCI	P	N	P-heterogeneity
Body fat percentage	0.158	0.129	0.188	2.00E-25	55667	0.098	0.065	0.132	1.00E-08	62345	0.03
BMI	0.057	0.034	0.079	8.00E-07	56668	0.037	0.011	0.063	0.005	63020	0.5
Body fat mass	0.190	0.146	0.233	2.00E-17	55679	0.128	0.077	0.178	7.00E-07	62345	0.2
body fat-free mass	-0.049	-0.090	-0.009	0.02	55861	-0.013	-0.038	0.012	0.3	62360	0.3
Type 2 diabetes	0.940	0.917	0.964	1.00E-06	2,686 vs. 52,598	0.949	0.916	0.983	0.003	1,317 vs. 60,605	0.9
Systolic blood pressure	-0.278	-0.391	-0.165	1.00E-06	56830	-0.237	-0.347	-0.127	0.00002	62856	0.9
Diastolic blood pressure	-0.104	-0.173	-0.035	0.003	56765	-0.088	-0.153	-0.024	0.007	62736	0.9
Hypertension	0.982	0.971	0.993	0.001	35,634 vs. 20,680	0.982	0.971	0.992	0.0006	29,950 vs. 32,697	1.0
Heart disease	0.963	0.944	0.983	0.0004	4,169 vs. 52,499	0.975	0.944	1.006	0.1	1,589 vs. 61,431	0.8

**Table S10.** Sensitivity analysis of the effect of a favourable adiposity genetic score on cardiometabolic disease risk in the UK Biobank study. NA: not available; LCI: lower confidence interval; UCI: upper confidence interval. Effects are per additional weighted copy of the adiposity increasing allele.

OUTCOME	BETA/OR	LCI	UCI	P	N
Systolic blood pressure (excluding those on blood pressure medication)	-0.139	-0.208	-0.069	0.00009	93443
Diastolic blood pressure (excluding those on blood pressure medication)	-0.030	-0.070	0.010	0.1	93289
Heart disease (those with heart attack as cases)	0.979	0.949	1.009	0.2	2,180 vs. 113,930
Type 2 diabetes (corrected for smoking)	0.944	0.925	0.964	4.00E-08	3,988 vs. 112,172
Systolic blood pressure (corrected for smoking)	-0.253	-0.332	-0.173	4.00E-10	118360
Diastolic blood pressure (corrected for smoking)	-0.096	-0.143	-0.048	0.00007	118173
Hypertension (corrected for smoking)	0.982	0.974	0.990	6.00E-06	65,080 vs. 52,827
Heart disease (corrected for smoking)	0.968	0.951	0.985	0.0002	5,684 vs. 112,950

**Table S11.** The effect of a favourable adiposity genetic score (using 7 SNPs associated with body fat percentage at  $p < 3E-5$ ) on measures of adiposity and cardiometabolic disease risk in the UK Biobank study. LCI: lower confidence interval; UCI: upper confidence interval. Effects are per additional weighted copy of the adiposity increasing allele.

OUTCOME	BETA/OR	LCI	UCI	P	N
Body fat percentage	0.190	0.162	0.217	4.82E-41	118012
BMI	0.061	0.040	0.082	1.219E-08	119688
Body fat mass	0.237	0.195	0.278	2.63E-29	118221
body fat-free mass	-0.031	-0.059	-0.002	0.03294344	118024
Type 2 diabetes	0.914	0.891	0.937	1.301E-12	4,003 vs. 113,203
Systolic blood pressure	-0.349	-0.446	-0.252	1.50E-12	120008
Diastolic blood pressure	-0.123	-0.181	-0.065	0.00002907	119821
Hypertension	0.975	0.965	0.984	1.09E-07	65,584 vs. 53,377
Heart disease	0.954	0.934	0.975	0.0000143	5,758 vs. 113,930

**Table S12.** The effect of genetic predisposition to favorable adiposity and BMI on risk of cardiometabolic disease outcomes. Effects are calculated comparing to the reference group in the UK Biobank study. LCI: Lower confidence interval; UCI: Upper confidence interval; P: p-value; N: total sample size.

Trait/disease	Category	BMIs mean (SD)	BETA/OR	LCI	UCI	P
Type 2 diabetes	High BMI Low FA	27.84 (4.9)	1.418	1.296	1.553	3.00E-14
Type 2 diabetes	High BMI High FA	28.04 (5.1)	1.255	1.151	1.368	2.00E-07
Type 2 diabetes	Low BMI Low FA	27.08 (4.6)	1.119	1.018	1.231	0.02
Type 2 diabetes	Low BMI High FA	27.13 (4.6)	reference	reference	reference	reference
Systolic blood pressure	High BMI Low FA	27.84 (4.9)	1.495	1.140	1.849	1.00E-16
Systolic blood pressure	High BMI High FA	28.04 (5.1)	1.019	0.690	1.347	1.00E-09
Systolic blood pressure	Low BMI Low FA	27.08 (4.6)	0.724	0.370	1.078	0.00006
Systolic blood pressure	Low BMI High FA	27.13 (4.6)	reference	reference	reference	reference
Diastolic blood pressure	High BMI Low FA	27.84 (4.9)	0.839	0.628	1.051	7.00E-15
Diastolic blood pressure	High BMI High FA	28.04 (5.1)	0.676	0.480	0.872	1.00E-11
Diastolic blood pressure	Low BMI Low FA	27.08 (4.6)	0.253	0.042	0.464	0.02
Diastolic blood pressure	Low BMI High FA	27.13 (4.6)	reference	reference	reference	reference
Hypertension	High BMI Low FA	27.84 (4.9)	1.128	1.090	1.168	1.00E-11
Hypertension	High BMI High FA	28.04 (5.1)	1.084	1.049	1.119	1.00E-06
Hypertension	Low BMI Low FA	27.08 (4.6)	1.050	1.014	1.087	0.006
Hypertension	Low BMI High FA	27.13 (4.6)	reference	reference	reference	reference
Heart disease	High BMI Low FA	27.84 (4.9)	1.101	1.019	1.190	0.02
Heart disease	High BMI High FA	28.04 (5.1)	1.092	1.016	1.173	0.02
Heart disease	Low BMI Low FA	27.08 (4.6)	1.042	0.964	1.127	0.3
Heart disease	Low BMI High FA	27.13 (4.6)	reference	reference	reference	reference



**Table S13.** The effect of genetic predisposition to favorable adiposity on risk of cardiometabolic disease outcomes using adiposity traits as covariates to test if they are mediators. Effects are per additional weighted copy of the adiposity increasing allele in the UK Biobank study. LCI: Lower confidence interval; UCI: Upper confidence interval; P: p-value; N: total sample size.

OUTCOME	COVARIAT	SEX	BETA/OR	LCI	UCI	P	N
Type 2 diabetes	None	Males	0.908	0.873	0.944	1E-6	55492
	Body fat percentage		0.854	0.820	0.890	5E-14	54286
	BMI		0.871	0.836	0.907	3E-11	55239
	Waist		0.869	0.834	0.905	1E-11	55427
	Waist-hip ratio		0.886	0.851	0.923	4E-9	55411
	None	Females	0.921	0.872	0.973	0.003	62196
	Body fat percentage		0.889	0.840	0.940	4E-5	61221
	BMI		0.889	0.840	0.941	4E-5	61881
	Waist		0.898	0.848	0.950	2E-4	62109
	Waist-hip ratio		0.940	0.888	0.994	0.03	62099
Systolic blood pressure	None	Males	-0.020	-0.028	-0.012	1E-6	56830
	Body fat percentage		-0.030	-0.038	-0.022	2E-13	55580
	BMI		-0.025	-0.033	-0.017	1E-9	56572
	Waist		-0.025	-0.033	-0.017	5E-10	56767
	Waist-hip ratio		-0.023	-0.031	-0.015	2E-08	56752
	None	Females	-0.017	-0.025	-0.009	2E-4	63178
	Body fat percentage		-0.022	-0.030	-0.015	9E-09	62185
	BMI		-0.019	-0.026	-0.011	1E-06	62856
	Waist		-0.015	-0.022	-0.007	1E-4	63092
	Waist-hip ratio		-0.009	-0.017	-0.002	0.01	63082

Diastolic blood pressure	None	Males	-0.012	-0.020	-0.004	0.005	56765
	Body fat percentage		-0.025	-0.033	-0.018	3E-10	55514
	BMI		-0.018	-0.025	-0.010	1E-5	56508
	Waist		-0.019	-0.027	-0.011	3E-6	56702
	Waist-hip ratio		-0.016	-0.024	-0.008	1E-4	56687
	None	Females	-0.011	-0.019	-0.003	0.007	63056
	Body fat percentage		-0.018	-0.026	-0.011	1E-6	62064
	BMI		-0.013	-0.020	-0.005	6E-4	62736
	Waist		-0.008	-0.015	0.000	0.05	62970
	Waist-hip ratio		-0.001	-0.009	0.007	0.8	62960
Hypertension	None	Males	0.971	0.954	0.989	0.001	56549
	Body fat percentage		0.951	0.933	0.968	9E-8	55303
	BMI		0.963	0.945	0.981	6E-5	56289
	Waist		0.961	0.943	0.978	2E-5	56484
	Waist-hip ratio		0.965	0.948	0.983	1E-4	56469
	None	Females	0.971	0.955	0.988	6E-4	62955
	Body fat percentage		0.959	0.943	0.976	2E-6	61967
	BMI		0.967	0.950	0.984	1E-4	62634
	Waist		0.975	0.958	0.992	0.004	62869
	Waist-hip ratio		0.987	0.970	1.003	0.1	62859
Heart disease	None	Males	0.943	0.913	0.974	4E-4	56936
	Body fat percentage		0.924	0.894	0.955	4E-6	55667
	BMI		0.930	0.900	0.961	1E-5	56668
	Waist		0.931	0.901	0.962	1E-5	56865

	<b>Waist-hip ratio</b>		0.936	0.906	0.967	7E-5	56849
	<b>None</b>	<b>Females</b>	0.960	0.913	1.010	0.1	63201
	<b>Body fat percentage</b>		0.940	0.893	0.990	0.02	62199
	<b>BMI</b>		0.956	0.909	1.006	0.08	62872
	<b>Waist</b>		0.961	0.914	1.011	0.1	63108
	<b>Waist-hip ratio</b>		0.978	0.930	1.029	0.4	63098